Source: Business Standard

Aurobindo Pharma: Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?

Aurobindo Pharma Ltd share price: The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to manufacture and market Dasatinib tablets

Read full article »
Aurobindo Pharma's Competitors | Aurobindo Pharma's News | Aurobindo Pharma's Financials
Stay up-to-date with the latest news on Aurobindo Pharma
Est. Annual Revenue
$1.0-5.0B
Est. Employees
10-50K
K.Nithyananda Reddy's photo - Managing Director of Aurobindo Pharma

Managing Director

K.Nithyananda Reddy

CEO Approval Rating

75/100

Read more
Stay up-to-date with the latest news on Aurobindo Pharma